Memantine for Executive Dysfunction in Adults With ADHD: A Pilot Study
Status:
Completed
Trial end date:
2013-08-01
Target enrollment:
Participant gender:
Summary
This is a 12-week clinical trial evaluating the efficacy and safety of memantine
hydrochloride (Namenda) in the treatment of executive function deficits (EFDs) in adults with
Attention Deficit Hyperactivity Disorder (ADHD) receiving open-label treatment with
OROS-Methylphenidate (OROS-MPH, Concerta). The study aims to examine the effects of treatment
with memantine on ADHD symptoms. Following screening procedures, memantine is prescribed in
randomized, double-blind fashion (equal chance of medication or placebo) for 12 weeks, along
with open-label OROS-MPH (everyone receives medication).
Phase:
N/A
Details
Lead Sponsor:
Massachusetts General Hospital
Collaborator:
The American Professional Society of ADHD and Related Disorders (APSARD)